Table 1.
Baseline characteristics for the whole cohort and distribution between patients with and without cardiovascular events during follow-up. Significance was reached when p < 0.05 (*).
| Total cohort | Event group | No event group | P value | |
|---|---|---|---|---|
| Mean ± SD/Median (IQR) /n (%) | Mean ± SD/Median (IQR) /n (%) | Mean ± SD /Median (IQR)/n (%) | ||
| Age (years) | 67.7 ± 9.6 | 72.1 ± 7.7 | 67.1 ± 9.7 | 0.056 |
| Male gender | 70 (58.3) | 8 (53.3) | 62 (59) | 0.440 |
| Prior myocardial infarction | 39 (32.5) | 8 (53.3) | 31 (29.5) | 0.064 |
| Prior ischemic stroke | 14 (11.7) | 5 (33.3) | 9 (8.6) | 0.016* |
| Prior PAD revascularization | 84 (70) | 12 (80) | 72 (68.9) | 0.281 |
| Current smoking | 53 (44.2) | 8 (53.3) | 45 (42.9) | 0.312 |
| Body Mass Index (kg/m2) | 26.5 ± 4.5 | 27.1 ± 5.2 | 26.4 ± 4.5 | 0.557 |
| Diabetes Mellitus type 2 | 31 (25.8) | 5 (33.3) | 26 (24.8) | 0.335 |
| Creatinine (µmol/l) | 90 (74–105) | 97 (81–154) | 86 (73–104) | 0.036* |
| Antiplatelet drugs | 120 (100) | 15 (100) | 105 (100) | 1.000 |
| Lipid-lowering drugs | 115 (95.8) | 13 (86.7) | 102 (97.1) | 0.058 |
| Antihypertensive drugs | 90 (75) | 11 (73.3) | 79 (75.2) | 0.908 |
| Rutherford classification | 0.090 | |||
| Rutherford 1 | 9 (7.5) | 1 (6.7) | 8 (7.6) | |
| Rutherford 2 | 34 (28.3) | 2 (13.3) | 32 (30.5) | |
| Rutherford 3 | 45 (37.5) | 4 (26.7) | 41 (39) | |
| Rutherford 4 | 32 (26.7) | 8 (53.3) | 24 (22.9) |
Significant values are in bold.